Advanced searches left 3/3

Growth - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 05 July 2022

* If you want to update the article please login/register

Genetic Causes of Growth Disorders

Sometimes the reason is apparent, as an example, growth hormone deficiency for growth asymmetry and a growth hormone excess for overgrowth. Some cases of severe growth disorders have inherited polygenic inheritance, while others seem to be inherited as a monogenic characteristic - reversive, dominant, or X-linked. We therefore recommend a research to determine novel genetic causes of idiopathic growth disorders using whole-exome sequencing. The primary aim of this research was to find novel causes of childhood growth disorders in order to enhance clinical diagnosis, prognosis, and response to therapy based on etiology, in order to provide more complete information into human growth regulation, which may lead to new therapeutic approaches. Because of their significance for this genetic approach, affected and unaffected family members will also be investigated.

Source link: https://clinicaltrials.gov/ct2/show/NCT02311322


Child Growth and Development in East London

Following written informed parental permission, a pilot screening program for Tower Hamlets 600 children under the age of 22. 5 years will be included in a pilot screening program. Pilot Aim 1, Pilot an automated growth screening algorithm that in Tower Hamlets 600 children under the age of 22. 5 years, will be launched in a pilot screening program. As part of the Healthy Child Programme, children will be identified when they have their 2-2. 5 years of service. Child height will then be measured as part of the National Child Measurement Programme at 4-5 years of age and linked to primary care data, enabling the growth-screening algorithm to be used to these three data points. The Royal London Hospital's paediatric endocrinology clinic at the Royal London Hospital will assess the 2% of children with the poorest growth in whom prior reports reveal a high incidence of medical disorders and contact parents. In addition, focus group discussions with caregivers and Health Visitors will be held to get an idea of how they feel about screening and identifying potential barriers to a larger roll out. Following the 2-2. 5 years of friendship, a subgroup of children will be invited to a more comprehensive developmental assessment to determine gross motor, fine motor, social, language, visual-spatial, and reasoning skills, which can be administered or guided by a child psychologist. Children with impaired neurodevelopment and are consequently at risk of poor school achievement, according to these results, which can be used to conduct sensitivity assessments to test the belief that linear growth failure alone or in combination with other factors.

Source link: https://clinicaltrials.gov/ct2/show/NCT05419336


Growth Hormone Administration and the Human Immune System

Both Study I and IB involve six people and are designed to determine whether pulsatile subcutaneous infusion of GH via a subcutaneous infusion pump will result in a healthy pulsatile GH pattern. The dose of GH used in Study IB will be three-fold higher than in Study I. Study I and IB will be completed first before moving to Study II. Study II, a placebo-controlled 12-week research involving 26 people divided into two groups: Group A and Group B, is a random, double-blinded, placebo-controlled 12-week trial involving 26 participants divided into two groups: Group A and Group B. Following an intervention, Group B will include 13 people receiving subcutaneous infusion of GH or placebo for four weeks, with an 8-week washout following removal. Medical relevance and aspired Outcome: This report will determine the effect of pulsatile growth hormone therapy on the human immune system and metabolic profile.

Source link: https://clinicaltrials.gov/ct2/show/NCT00663611


Fetal Growth Evaluation by Three-Dimensional Ultrasound

Fetal growth abnormalities, such as macrosomia and intrauterine growth retardation, are a contributing factor in increased perinatal mortality in the United States. This protocol includes two research arms and emphasizes the ability of 3D ultrasound to safely measure fetal soft tissue as an indicator of generalized nutritional status. Following delivery, neonatal percent body fat and lean body mass will be measured by noninvasive air displacement plethymography. Infant body composition results will enable the precise classification of neonatal growth outcomes for subsequent comparisons to prenatal sonographic studies. Following delivery to test results in percent body fat and fat-free mass, a maximum of 50 newborns from this cross-sectional arm will also be re-evaluated for infant body composition at 1 and two weeks. According to this Protocol, the subject recruitment ceiling for this Protocol would be + or 4,518 total subjects.

Source link: https://clinicaltrials.gov/ct2/show/NCT00340171


Natural History of Craniofacial Anomalies and Developmental Growth Variants

Craniofacial anomalies at birth, such as hemifacial microsomia, or common, such as dentofacial deformities such as the Habsburg Jaw or mandibular prognathism that becomes apparent as a child enters puberty, may be rare and present at birth. The primary objectives of this report are: To describe rare and common craniofacial anomalies using both extensive clinical evaluations, 3D cone-beam computed geometric morphometric and surface morphology, and surface morphology to determine genetic variants for rare and common craniofacial abnormalities. The second aim is to establish a curated craniofacial registry and compile results pertaining to clinically indicated procedures and services at the NIH for the treatment of craniofacial disorders and anomalies. Both children and adults have been affected by two specific conditions that influence facial skeletal growth: hemifacial microsomia and mandibular prognathism in children and adults.

Source link: https://clinicaltrials.gov/ct2/show/NCT02639312


Targeting Human Milk Fortification to Improve Preterm Infant Growth and Brain Development

This paper addresses a knowledge gap in understanding the most effective human milk fortification in the neonatal intensive care unit. The study period begins when infants have reached full-fledge human milk intakes had increased to 24 kcal per ounce. To reach the total daily fluid volume, available maternal milk will be mixed with donor milk, according to a point-of-care human milk analyzer. We will individually target fortification with additional protein and/or energy so that the "base" milk has always contains protein 1 g/dL and electricity 67 kcal/dL. Physical fitness will improve during the diet intervention period, including weight, length, and head circumference, as well as body composition with air displacement plethysmography at the end of the diet intervention.

Source link: https://clinicaltrials.gov/ct2/show/NCT03977259

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions